


Korean Cancer Association

Room 1824, Gwanghwamun Officia, 92 Saemunan-ro,

Jongno-gu, Seoul 03186, Korea

Tel +82-2-792-1486 Fax + 82-2-792-1410 E-mail cancer@kams.or.kr

www.cancer.or.kr



www.cancer.or.kr




45th Annual Meeting & 5th International Cancer Conference

June 20(Thu) – 21(Fri), 2019
Seoul Dragon City Hotel, Seoul, Korea



Korean Cancer Association



45th Annual Meeting of Korean Cancer Association & 5th International Cancer Conference

Date	June 20-21, 2019
Venue	Seoul Dragon City Hotel, Seoul, Korea
Host	Korean Cancer Association
Official Language	English, Korean
Website	www.cancer.or.kr

Contents

- 01 Welcome Message
- 02 Plenary Speakers
- 03 Abstract submission and Registration
- 04 Program at a Glance
- 08 Scientific Program

Major Sponsors



Welcome Message

Dear Colleagues and Friends,

It gives us great pleasure to invite all of you to the 45th Annual Meeting of Korean Cancer Association and the 5th International Cancer Conference, which will be held from June 20 to 21, 2019, in Seoul, Korea.

The 44th Annual Meeting has gathered more than 1,600 participants including clinicians, researchers, and scientists and KCA has successfully shown the scientific authority in the field of oncology. We have no doubt to provide participants an opportunity to share and learn innovative knowledge by cancer experts through our meeting.

Following the success of 44th Annual Meeting, the 2019 meeting will be the premier platform to gain an updated view on cancer and present a wide spectrum of oncology from the perspectives of advances in cancer research and related biomedical science. The various thematic sessions from plenaries to posters will show up-to-date scientific knowledge and allow multiple opportunities to have in-depth discussions.

We will make any possible effort to make sure that your participation will be scientifically rewarding and a pleasurable experience. So, please mark your calendar and be sure to attend the 2019 meeting.

We look forward to welcoming you in Seoul, Korea!

Sincerely yours,

Hee-Sug Ryu, M.D., Ph.D.
President
Korean Cancer Association

Hyun Cheol Chung, M.D., Ph.D.
Chairman, Board of Directors
Korean Cancer Association

Sun Young Rha, M.D., Ph.D.
Chairperson, Scientific Committee
Korean Cancer Association

Plenary Speakers



Walter J. Curran, MD, FACR, FASCO
 Executive Director, Winship Cancer Institute of Emory University, USA

Progress through the new American NCI National Clinical Trials Network: NRG oncology as a case study



Thomas Gajewski, MD, PhD
 Professor, University of Chicago, USA

Tumor and host factors regulating immunotherapy efficacy versus resistance



Yeul Hong Kim, MD, PhD
 Professor, Korea University College of Medicine, Korea

The complex path to cancer precision medicine



Gou Young Koh, MD, PhD
 Director, IBS Center for Vascular Research
 Professor, KAIST, Korea

How do tumor cells grow within lymph node?

Call for Abstracts

Extended Abstract Submission Deadline: by April 13, 2019

● Presentation Type

- **Poster Presentation**
- **International Session (Oral): Presented in English**
- **Oral Presentation: Presented in Korean**
- **Outstanding Abstract Session: Selected original articles that is not presented in int'l conferences; Presented in English**

Outstanding Abstract Session

Selected presentations who demonstrate the highest levels of scientific and clinical impact will be recognized by scientific committee. In this session, original articles that is not presented in international conferences are required and will be presented in English. Each presenters will be awarded USD 1,000.

● Travel Awards (Overseas/International)

The scientific committee will select fifteen award winners from overseas presenters in recognition of their outstanding achievements and contributions to scientific development in the field of Cancer.

No. of Winners	15
Prize Money	USD 1,000

Registration

- Register online at the website of the 45th Annual Meeting of KCA & 5th International Cancer Conference. (www.cancer.or.kr)

● Registration fee

Category	Pre-registration(Closes May 25, 2019)	On-site Registration
Doctor / Professor	USD 100	USD 120
Student & Trainee *	USD 50	USD 70

- Registration Fees Include conference kit and lunches on June 20 & 21.
- If you register as a student or a trainee, please submit a proof of status issued within 6 months of the registration.

● Payment Method

- 1) Online Credit Card : Registration fees may be paid by credit card only through the secure online registration system at www.cancer.or.kr.
- 2) Bank Transfer

Bank Name	Account Holder	Account Number	SWIFT Code
Shinhan Bank	Korean Cancer Association	180-005-733896	SHBKKRSE

- The transfer must be in the registrant's name and must be stated on the receipt.
- All bank charges are the responsibility of the applicant.
- A copy of the receipt of the bank remittance should be sent to the secretariat by e-mail or fax.

Thursday, June 20

Location	3F		
Room	HANRA A	HANRA B	HANRA C
09:00-10:40	ES-1 <small>KOR</small> Clinical oncology for basic scientists	ES-2 <small>KOR</small> Recent advances in understanding and treating advanced GI cancer	ES-3 <small>KOR</small> Optimal combination of radiation therapy and immune checkpoint blockades
10:40-11:00	Coffee Break		
11:00-11:30	Plenary Lecture 1 <small>ENG</small> Dr. Gou Young Koh How do tumor cells grow within lymph node?		
11:30-12:20	Plenary Lecture 2 <small>ENG</small> Dr. Walter J. Curran Progress through the new American NCI National Clinical Trials Network: NRG Oncology as a case study		
12:20-13:20	LS-1 <small>ENG</small> SANOFI GENZYME	LS-2 <small>ENG</small> Servier	LS-3 <small>ENG</small> AstraZeneca
13:20-15:00	SP-1 <small>ENG</small> Conquering stomach cancer, the major cancer killer in Korea and Japan * KCA-JCA Joint Symposium	SP-2 <small>ENG</small> Tissue agnostic drug development	SP-3 <small>ENG</small> Updates on head and neck-thyroid oncology * KCA-CSCO Joint Symposium
15:00-15:20	Coffee Break		
15:20-17:00	SP-7 <small>ENG</small> Current status of precision medicine in colorectal cancer * KCA-JSCO Joint Symposium	SP-8 <small>ENG</small> Advanced and innovative clinical research	SP-9 <small>ENG</small> Recent precision medicine in gynecologic and breast cancer * KCA-KSGO Joint Symposium
17:00-18:00	Oral Presentations <small>KOR</small> / International Sessions <small>ENG</small>		

Session Remarks

Symposium 1 Joint Symposium of KCA & Japanese Cancer Association(JCA)

Symposium 3 Joint Symposium of KCA & Chinese Society of Clinical Oncology(CSCO)

Symposium 6 Joint Symposium of KCA & Korean Society for Vascular Biology and Medicine(KVBM)

Symposium 7 Joint Symposium of KCA & Japan Society of Clinical Oncology(JSCO)

Symposium 9 Joint Symposium of KCA & Korean Society of Gynecologic Oncology(KSGO)

Symposium 10 Joint Symposium of KCA & Korea Genome Organization(KOGO)

Thursday, June 20

3F	4F		5F	
SHILLA A	BAEKJE A	BAEKJE B	GOGURYEO	BAEKDU
YIS-1 <small>KOR</small> Korean Young Investigator Symposium				
Coffee Break				
LS-4 <small>ENG</small> Pfizer				
SP-4 <small>ENG</small> Immunotherapy for rare cancer	SP-5 <small>KOR</small> Strategic plans of improving multicenter clinical trials	SP-6 <small>ENG</small> Vascular regulation of cancer progression * KCA-KVBM Joint Symposium	MC-1 <small>ENG</small> Recent updates in the development of immune-therapy for cancer treatment	
Coffee Break				
SP-10 <small>ENG</small> Omics for innovative clinical cancer research * KCA-KOGO Joint Symposium	SP-11 <small>KOR</small> Exchange and cooperation of oncology between the South and the North Korea	IS-1 <small>ENG</small> International Session	MC-2 <small>ENG</small> GC academy: Special talk for antiangiogenic agents in mGC treatment	
Oral Presentations <small>KOR</small> / International Sessions <small>ENG</small>				

Poster Presentation 1 (09:00-17:00)

Language

ENG Sessions in English

KOR Sessions in Korean

ES : Educational Session MC : Master Class

SP : Symposium LS : Luncheon Symposium

IS : International Session (Oral presentations in English)

Friday, June 21

Location	3F		
Room	HANRA A	HANRA B	HANRA C
09:00-10:00	Outstanding Abstract Session ENG		YIS-2 KOR Overseas Young Investigator Symposium
10:00-10:20	Coffee Break		
10:20-10:50	Plenary Lecture 3 ENG Dr. Yeul Hong Kim The complex path to cancer precision medicine		
10:50-11:40	Plenary Lecture 4 ENG Dr. Thomas Gajewski Tumor and host factors regulating immunotherapy efficacy versus resistance		
11:50-12:50	LS-5 ENG MSD		LS-6 ENG Roche
12:50-13:30	KCA General Assembly		
13:40-15:20	SP-12 ENG Basic immunology primer * KCA-SITC Joint Symposium I	SP-13 ENG Immune targeted biomarkers in therapeutic decision making * KCA-KSP Joint Symposium	SP-14 KOR Promising anti-cancer drug pipeline in pre-clinical and clinical stages in Korea
15:20-15:40	Coffee Break		
15:40-17:20	SP-16 ENG Clinical or translational session * KCA-SITC Joint Symposium II	SP-17 KOR Microbiology and microbiome in cancer * KCA-KSLM Joint Symposium	SP-18 ENG Current practice and dilemma in oligometastatic disease of lung cancer
17:30-18:30	Closing Reception @ BAEKDU		

Session Remarks

Symposium 12, 16 Joint Symposium of KCA & Society for Immunotherapy of Cancer(SITC)

Symposium 13 Joint Symposium of KCA & The Korean Society of Pathologists(KSP)

Symposium 14 National OncoVenture Symposium

Symposium 17 Joint Symposium of KCA & Korean Society for Laboratory Medicine(KSLM)

Friday, June 21

3F	4F		5F		
SHILLA A	BAEKJE A	BAEKJE B	GOGURYEO	BAEKDU	
	Oral Presentations KOR International Sessions ENG			Poster Presentation 2 (09:00-17:00)	
Coffee Break					
LS-7 ENG Lilly					
SP-15 ENG Tumor microenvironment of solid cancer	Oral Presentations KOR International Sessions ENG		MC-3 ENG How to generate and utilize RWE (real-world evidence) in oncology		
Coffee Break					
SP-19 KOR 암관련학회협의체 심포지엄	Oral Presentations KOR International Sessions ENG				
Closing Reception @ BAEKDU					

Language

ENG Sessions in English

KOR Sessions in Korean

SP : Symposium

MC : Master Class

LS : Luncheon Symposium

IS : International Session
(Oral presentations in English)

Plenary Lecture 1 ENG

11:00-11:30, Hanra

How do tumor cells grow within lymph node?

Gou Young Koh (IBS Center for Vascular Research / KAIST)

Plenary Lecture 2 ENG

11:30-12:20, Hanra

Progress through the new American NCI**National Clinical Trials Network: NRG Oncology as a case study**

Walter J. Curran (Winship Cancer Institute of Emory University, USA)

Educational Session 1 KOR

09:00-10:40, Hanra A

Clinical oncology for basic scientists**1 Staging and pathologic features related to cancer biology**

Kyu-Rae Kim (University of Ulsan College of Medicine)

2 Oncologic imaging: Evolving images for evolving treatments

Kyung Won Kim (University of Ulsan College of Medicine)

3 Armamentarium in medical oncology: Old and new

Inkeun Park (Gachon University College of Medicine)

4 Clinical trials: How to add translational components

Yoonji Choi (Korea University College of Medicine)

Educational Session 2 KOR

09:00-10:40, Hanra B

Recent advances in understanding and treating advanced GI cancer**1 Pressurized intraperitoneal aerosol chemotherapy**

Sang Hoon Ahn (Seoul National University College of Medicine)

2 Value of extra nodal tumor deposit and extramural vascular invasion in colorectal cancer

Sun Jin Park (Kyung Hee University College of Medicine)

3 Alternative preoperative treatment in advanced rectal cancer

Hye Jin Kim (Kyungpook National University School of Medicine)

4 Update of treatment for peritoneal metastasis in gastric cancer

Jong-Han Kim (Korea University College of Medicine)

Educational Session 3 KOR

09:00-10:40, Hanra C

Optimal combination of radiation therapy and immune checkpoint blockades**1 Radiation therapy and anti-tumor immunity; immunological mechanisms of abscopal effect**

SaeGwang Park (Inje University College of Medicine)

2 A strategy of the combination of radiotherapy and immune checkpoint blockade

Jinho Kim (Seoul National University College of Medicine)

3 Propagation of abscopal effect from local therapy

Kyong Hwa Park (Korea University College of Medicine)

YIS-1 KOR

09:00-10:40, Shilla A

Korean Young Investigator Symposium**1 Application of proteomics in translational cancer research**

Jae-Young Kim (Chungnam National University)

2 Extracellular vesicles in cancer: Cell-to-cell mediators of metastasis

Han Sang Kim (Yonsei University College of Medicine)

3 Application of robotic surgery for advanced gynecologic cancers

Jiheum Paek (Ajou University School of Medicine)

4 The defense mechanisms of polarized epithelial cells to suppress EMT and tumor metastasis

HaeYun Jung (Sungkyunkwan University School of Medicine)

Symposium 1 ENG

13:20-15:00, Hanra A

* Joint Symposium of KCA & Japanese Cancer Association(JCA)

Conquering stomach cancer, the major cancer killer in Korea and Japan

1 Epigenetic alterations in gastric epithelial and stromal cells as diagnostic and therapeutic targets

Toshikazu Ushijima (National Cancer Center Research Institute, Japan)

2 Integrated proteogenomic analysis of gastric cancers

Daehee Hwang (Seoul National University School of Biological Sciences)

3 Stem cell origin of gastric cancers and their niche

Yoku Hayakawa (The University of Tokyo, Japan)

4 Targeting interaction between fibrotic stroma and cancer cell in gastric cancer

Hoon Hur (Ajou University School of Medicine)

Symposium 2 ENG

13:20-15:00, Hanra B

Tissue agnostic drug development

1 The first biomarker-defined tumor indication: Pembrolizumab for MSI-H tumors

Kenneth Emancipator (MSD, USA)

2 Development of Larotrectinib in NTRK fusion positive tumors

To be announced

3 Challenges of tissue agnostic drug approval and utility

Myung-Ju Ahn (Sungkyunkwan University School of Medicine)

Symposium 3 ENG

13:20-15:00, Hanra C

* Joint Symposium of KCA & Chinese Society of Clinical Oncology(CSCO)

Updates on head and neck-thyroid oncology

To be announced

Symposium 4 ENG

13:20-15:00, Shilla A

Immunotherapy for rare cancer

1 Unleashing the innate and adoptive immune systems for the treatment of pediatric solid tumors

Robbie G. Majzner (Stanford University School of Medicine, USA)

2 Immune checkpoint blockade immunotherapy for advanced solid tumor of childhood

Yasushi Fuchimoto (International University of Health and Welfare School of Medicine, Japan)

3 Exploring combination therapy with B cell and monocyte-based cancer vaccines

Chang-Yuil Kang (Seoul National University College of Pharmacy)

Symposium 5 KOR

13:20-15:00, Baekje A

Strategic plans of improving multicenter clinical trials

1 Establishing database platform of KGOG

Chel Hun Choi (Sungkyunkwan University School of Medicine)

2 Beyond the specialty: Integration of inter-departmental ability

Yong Wha Moon (CHA University School of Medicine)

3 Tips and tricks of recruiting study population

Won Park (Sungkyunkwan University School of Medicine)

4 Development of 'good' clinical trial protocol

Sokbom Kang (National Cancer Center)

5 Panel Discussion**Symposium 6** ENG

13:20-15:00, Baekje B

* Joint Symposium of KCA & Korean Society for Vascular Biology and Medicine (KVBM)

Vascular regulation of cancer progression

1 Mitochondrial UQCRB, a new player in tumor angiogenesis

Ho Jeong Kwon (Yonsei University)

2 Endothelial Notch signaling promotes tumor progression and metastasis

Andreas Fischer (German Cancer Research Center(DKFZ), Germany)

3 Deciphering the origin of somatic mutations in brain tumors

Jeong Ho Lee (Korea Advanced Institute of Science and Technology)

4 Vascular abnormalities in mouse brain tumor models

Injune Kim (Korea Advanced Institute of Science and Technology)

Symposium 7 ENG

15:20-17:00, Hanra A

* Joint Symposium of KCA & Japan Society of Clinical Oncology(JSCO)

Current status of precision medicine in colorectal cancer

- ❶ **Recent challenges for precision medicine in colorectal cancer**
Hideo Baba (Graduate School of Medical Sciences, Kumamoto University, Japan)
- ❷ **Next-generation sequencing-based clinical sequencing: Toward precision medicine in colorectal cancer**
Toshifumi Wakai (Niigata University Graduate School of Medical and Dental Sciences, Japan)
- ❸ **Application of clinical NGS in colorectal cancer: Asan Medical Center experience**
Jihun Kim (University of Ulsan College of Medicine)
- ❹ **Precision medicine in colorectal cancer: Case review**
Jin Won Kim (Seoul National University College of Medicine)

Symposium 8 ENG

15:20-17:00, Hanra B

Advanced and innovative clinical research

- ❶ **Pragmatic clinical research and barriers**
Edward Kim (Atrium Health Levine Cancer Institute, USA)
- ❷ **Untold reality in medical device development**
Seung-June Oh (Seoul National University College of Medicine)
- ❸ **Innovations in clinical trials and future**
Jee Hyun Kim (Seoul National University College of Medicine)

Symposium 9 ENG

15:20-17:00, Hanra C

* Joint Symposium of KCA & Korean Society of Gynecologic Oncology(KSGO)

Recent precision medicine in gynecologic and breast cancer

- ❶ **Current status and future of genetic test**
Myong Cheol Lim (National Cancer Center)
- ❷ **Mismatch repair gene and gynecologic cancer**
Min Chul Choi (CHA University School of Medicine)
- ❸ **BRCAness and synthetic lethality**
Sung Jong Lee (The Catholic University of Korea College of Medicine)
- ❹ **Surveillance and risk-reducing strategies for breast cancer in women with BRCA mutations**
Hyung Seok Park (Yonsei University College of Medicine)
- ❺ **Precision medicine in gynecologic cancer**
Woong Ju (Ewha Womans University College of Medicine)

Symposium 10 ENG

15:20-17:00, Shilla A

* Joint Symposium of KCA & Korea Genome Organization(KOGO)

Omics for innovative clinical cancer research

- ❶ **Studies on developing prediction models based on cancer transcriptome and clinical information**
Minho Lee (The Catholic University of Korea)
- ❷ **Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors**
Mirang Kim (Korea Research Institute of Bioscience & Biotechnology)
- ❸ **Genomic research and clinical applications in breast cancer**
Wonshik Han (Seoul National University College of Medicine)
- ❹ **Molecular classification reveals new driver transcripts in liver cancer**
Hyun Goo Woo (Ajou University School of Medicine)

Symposium 11 KOR

15:20-17:00, Baekje A

Exchange and cooperation of oncology between the South and North Korea

- ① **The galapagos of the medical research field - An opportunity for the future of medicine in the Korean Peninsula**
Sin-Gon Kim (Korea University College of Medicine)
- ② **R&D initiatives in DPRK**
Hee Young Shin (Seoul National University Institute for Peace and Unification Studies)
- ③ **Experience of healthcare project between the South & North Korea**
Yoonsang Lee (Nanum International)

Master Class 1 ENG

13:20-15:00, Goguryeo

Recent updates in the development of immune-therapy for cancer treatment

- ① **Recent updates in combination of pembrolizumab and TKIs**
To be announced
- ② **Pembrolizumab for MSI-H solid tumor**
To be announced
- ③ **Durable response after discontinuation of pembrolizumab and re-challenge for patients experiencing progression after response**
To be announced

Master Class 2 ENG

15:20-17:00, Goguryeo

GC academy: Special talk for antiangiogenic agents in mGC treatment

- ① **How do we go through the HER+ GC?**
Jin Soo Kim (Seoul National University College of Medicine)
- ② **From the start to future in antiangiogenic agent in GC**
Sun Young Rha (Yonsei University College of Medicine)
- ③ **Real world evidence of ramucirumab in GC**
Keun-Wook Lee (Seoul National University College of Medicine)

Luncheon Symposium 1 ENG **SANOBI GENZYME**

12:20-13:20, Hanra A

Individualized treatment decision for optimal sequence in mCRC, with aflibercept

To be announced

Luncheon Symposium 2 ENG **Servier**

12:20-13:20, Hanra B

Liposomal irinotecan, new hope for the treatment of metastatic pancreatic cancer

Changhoon Yoo (University of Ulsan College of Medicine)

Luncheon Symposium 3 ENG **AstraZeneca**

12:20-13:20, Hanra C

Cutting-edge front-line treatment for advanced non-small cell lung cancer

Tae Min Kim (Seoul National University College of Medicine)

Luncheon Symposium 4 ENG **Pfizer**

12:20-13:20, Shilla A

Therapeutic strategy for maximizing overall survival for ALK/ROS1+ NSCLC

Takashi Seto (Kyushu Cancer Center, Japan)

International Session 1 ENG

15:20-17:00, Baekje B

Oral Presentations KOR

17:00-18:00, Hanra & Baekje

International Sessions ENG**Poster Presentation 1**

09:00-17:00, Baekdu

Plenary Lecture 3 ENG

10:20-10:50, Hanra

The complex path to cancer precision medicine

Yeul Hong Kim (Korea University College of Medicine)

Plenary Lecture 4 ENG

10:50-11:40, Hanra

Tumor and host factors regulating immunotherapy efficacy versus resistance

Thomas Gajewski (University of Chicago, USA)

YIS-2 KOR

09:00-10:00, Hanra C

Overseas Young Investigator Symposium**1 Mechanisms underlying synergy of Topo I and mTOR co-inhibition in MPNSTs**

Dong Hyuk Ki (Harvard Medical School/Dana-Farber Cancer Institute, USA)

2 Tumor interferon signaling: Implications for cancer immunotherapy

Daniel Sanghoon Shin (David Geffen School of Medicine at UCLA, USA)

3 Advancing the promise of chemoimmunotherapy in solid tumors

Youngwook Won (University of Arizona College of Medicine, USA)

Symposium 12 ENG

13:40-15:20, Hanra A

*** Joint Symposium of KCA & Society for Immunotherapy of Cancer(SITC)****Basic immunology primer**

To be announced

Symposium 13 ENG

13:40-15:20, Hanra B

*** Joint Symposium of KCA & The Korean Society of Pathologists(KSP)****Immune targeted biomarkers in therapeutic decision making****1 Comparison of PD-L1 assays in urothelial carcinoma**

Kyu Sang Lee (Seoul National University College of Medicine)

2 Pathologic interpretation of immune biomarkers in gastric cancer

Hyunki Kim (Yonsei University College of Medicine)

3 Molecular basis of immune response heterogeneity in colorectal cancers: potential biomarkers

Jung Ho Kim (Seoul National University College of Medicine)

4 Genomic features associated with transcriptome-based cancer immunoprofiling

Tae-Min Kim (The Catholic University of Korea College of Medicine)

Symposium 14 KOR

13:40-15:20, Hanra C

*** National OncoVenture Symposium****Promising anti-cancer drug pipeline in pre-clinical and clinical stages in Korea****1 Campaign NOV1801; Anti-4-1BB antibody, an immune checkpoint regulator**

Joong Won Lee (Eutilex)

2 Fast follower-Best in class strategy, Pan-TRK inhibitor (NOV1601)

Sang-Yoon Lee (HANDOK)

3 Development of NOV140101(IDX-1197); A novel, selective, and highly potent PARP inhibitor

SungKu Choi (Ildong Pharmaceutical)

Symposium 15 ENG

13:40-15:20, Shilla A

Tumor microenvironment of solid cancer

- ① **Single cell RNA-seq in tumor microenvironment**
Semin Lee (Ulsan National Institute of Science and Technology)
- ② **Targeting CAF-TAM interaction to inhibit cancer metastasis**
Darren Reece Williams (Gwangju Institute of Science and Technology)
- ③ **Cancer-restraining cancer-associated fibroblasts and their roles in tumor progression and immunity**
Atsushi Enomoto (Nagoya University, Japan)
- ④ **Tumor microenvironment remodeling by intratumoral oncolytic virus to enhance immune checkpoint blockade**
Chan Kim (CHA University School of Medicine)

Symposium 16 ENG

15:40-17:20, Hanra A

* Joint Symposium of KCA & Society for Immunotherapy of Cancer(SITC)

Clinical or translational session

To be announced

Symposium 17 KOR

15:40-17:20, Hanra B

* Joint Symposium of KCA & Korean Society for Laboratory Medicine(KSLM)

Microbiology and microbiome in cancer

- ① **Neutropenic fever in cancer patients**
Dong-Gun Lee (The Catholic University of Korea College of Medicine)
- ② **Metagenomic analysis**
Ju Sun Song (Green Cross Genome)
- ③ **Metagenomics in immuno-oncology drug era**
Han Soo Park (Gwangju Institute of Science and Technology)

Symposium 18 ENG

15:40-17:20, Hanra C

Current practice and dilemma in oligometastatic disease of lung cancer

- ① **Pathological and molecular characterization of oligometastatic disease**
Dong Hoon Shin (Pusan National University School of Medicine)
- ② **Surgical treatment of oligometastatic disease**
Hyun Koo Kim (Korea University College of Medicine)
- ③ **Radiotherapy for oligometastatic disease of lung cancer**
Yang-Gun Suh (National Cancer Center)
- ④ **Systemic therapy update in oligometastatic disease**
Sook Hee Hong (The Catholic University of Korea College of Medicine)

Symposium 19 KOR

15:40-17:20, Shilla A

암관련학회협의체 심포지엄

- ① **CAM use in Korean cancer patients**
Jung Hye Kwon (Hallym University College of Medicine)
- ② **Issues in off-label use for rare cancer**
Dae Ho Lee (University of Ulsan College of Medicine)
- ③ **Cancer survivorship**
Ji Soo Park (Yonsei University College of Medicine)
- ④ **Panel Discussion**

Master Class 3 ENG

13:40-15:20, Goguryeo

How to generate and utilize RWE (real-world evidence) in oncology

To be announced

Luncheon Symposium 5 ENG **MSD**

11:50-12:50, Hanra AB

The evolution from “Standard-of-Care” to “Standard-of-Survival”:
Unfolding the quantum leap in mNSCLC

To be announced

Luncheon Symposium 6 ENG **Roche**

11:50-12:50, Hanra C

The evolving power of immunotherapy: Atezolizumab in advanced lung cancer

To be announced

Luncheon Symposium 7 ENG **Lilly**

11:50-12:50, Shilla A

An optimal post-progression treatment option to improve advanced
gastric cancer patient outcomes: Clinical experiences with ramucirumab

Keun-Wook Lee (Seoul National University College of Medicine)

Outstanding Abstract Session ENG

09:00-10:00, Hanra AB

Oral Presentations KOR

09:00-10:00, Baekje AB

International Sessions ENG**Oral Presentations** KOR

13:40-15:20, Baekje AB

International Sessions ENG**Oral Presentations** KOR

15:40-17:20, Baekje AB

International Sessions ENG**Poster Presentation 2**

09:00-17:00, Baekdu